Abivax SA ADR (ABVX)
NASDAQ: ABVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 87.80 +0.91%
ABVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.59B
- EPS (TTM)
- -$6.08
- Dividend yield
- None
- 52-week range
- 69.81 – 148.83
- Day range
- 86.00 – 88.46
- Volume / Avg
- 1.39M / 1.09M
- Beta
- —
- Shares outstanding
- 87.27M
52-week range
ABVX stock today
Abivax SA (ABVX) closed at $87.01 on Oct 7, down 1.37% (-$1.21), versus the S&P 500's 0.22% decline. Shares are 41.5% below their 52-week high of $148.83, set on Dec 24, 2025 and 24.6% above the 52-week low of $69.81, in the middle of the past year's range. ABVX is down 35.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 0.0%.
Abivax SA has posted a net loss over the last twelve months (EPS of -$6.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Abivax SA
Company profileABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marc M. P. de Garidel M.B.A.
- Headquarters
- Paris
- Employees
- 98
- IPO year
- 2023
- Website
- abivax.com
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$164.00+88.48%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ABVX news
All ABVX newsAbivax SA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs ABVX |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs ABVX |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs ABVX |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs ABVX |
| ALKSAlkermes plc | 41.45 | -0.49% | $6.95B | vs ABVX |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs ABVX |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | -3.18% | $6.84B | vs ABVX |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs ABVX |
Indexes, lists and sector
Abivax SA stock FAQ
What is Abivax SA's stock price today?
ABVX last traded at $87.01 as of Oct 7, 4:00 PM EDT, down 1.37% on the day. Prices are delayed at least 15 minutes.
Who is Abivax SA's CEO?
Mr. Marc M. P. de Garidel M.B.A. is the chief executive officer of Abivax SA ADR, which has about 98 employees.
What is the ABVX 52-week high?
The 52-week high for ABVX is $148.83 and the 52-week low is $69.81. The stock is currently 41.5% below its high.